secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001104659-24-000579
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium 2024 guidance: revenue $580-595M, adj. EBITDA $380-395M, $150M buyback
--------------------------------------------------------------------------------

- FY2024 product revenue net expected $580M-$595M; adjusted EBITDA $380M-$395M.
- Board authorized $150M share repurchase program through June 30, 2025.
- Xtampza ER gross-to-net improving to 56%-58% after renegotiations covering 30% of scripts.
- Belbuca renegotiated major Medicare Part D contract, reducing rebate, and won new plan (~1M lives).
- Returned $75M to shareholders in 2023 under prior buyback, including $25M accelerated repurchase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924000579/0001104659-24-000579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924000579/tm241446d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-000579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer